A Peak Year For Drug Approvals, But Can R&D Keep Up With FDA?
This article was originally published in RPM Report
Executive Summary
FDA topped 40 new molecular entity approvals in 2014, leaving no doubt that the agency’s drug review group is operating at peak efficiency. But it is still far from clear that drug development is out of the doldrums.